Novel agents in the treatment of multiple myeloma: a review about the future
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel agents in the treatment of multiple myeloma: a review about the future
Authors
Keywords
Multiple myeloma, Novel agents, Immunomodulators, Proteasome inhibitors, Alkylating agents, AKT inhibitors, BTK inhibitors, CDK inhibitors, HDACIs, IL-6 inhibitors, Kinesin spindle protein inhibitors, Monoclonal antibodies, PI3K inhibitors
Journal
Journal of Hematology & Oncology
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-06-30
DOI
10.1186/s13045-016-0282-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Daratumumab in multiple myeloma
- (2016) S Vincent Rajkumar LANCET
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Relapsed Multiple Myeloma after Autologous Stem Cell Transplant
- (2015) Sarah A. Holstein et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma
- (2015) P. Moreau et al. BLOOD
- Treatment options for relapsed and refractory multiple myeloma
- (2015) A. K. Nooka et al. BLOOD
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
- (2015) P. G. Richardson et al. BLOOD
- Frontline therapy of multiple myeloma
- (2015) P. Moreau et al. BLOOD
- Smoldering multiple myeloma
- (2015) S. V. Rajkumar et al. BLOOD
- Pathogenesis beyond the cancer clone(s) in multiple myeloma
- (2015) G. Bianchi et al. BLOOD
- Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
- (2015) David H. Vesole et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma
- (2015) Joseph R. Mikhael et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
- (2015) Yuko Mishima et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma
- (2015) Douglas W. Sborov et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bendamustine in multiple myeloma
- (2015) Massimo Gentile et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
- (2015) Patricia M. LoRusso et al. INVESTIGATIONAL NEW DRUGS
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma
- (2015) Sally K. Martin et al. LEUKEMIA RESEARCH
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
- (2015) Salma Afifi et al. PHARMACOTHERAPY
- Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
- (2015) Paul G Richardson et al. Expert Review of Clinical Pharmacology
- A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
- (2014) Robert Z. Orlowski et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
- (2014) I-Jun Lau et al. ANNALS OF HEMATOLOGY
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
- Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma
- (2014) J. San-Miguel et al. BLOOD
- Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
- (2014) S. Bringhen et al. BLOOD
- The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
- (2014) A. Spencer et al. BLOOD
- Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
- (2014) S. K. Kumar et al. BLOOD
- Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
- (2014) P. G. Richardson et al. BLOOD
- Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
- (2014) Q. Dou et al. CURRENT CANCER DRUG TARGETS
- Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies
- (2014) Tadeusz Robak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- AKT as a therapeutic target in multiple myeloma
- (2014) Niamh A Keane et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial
- (2014) P. Rodon et al. HAEMATOLOGICA
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
- (2014) Shaji K Kumar et al. LANCET ONCOLOGY
- Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
- (2014) M A Dimopoulos et al. LEUKEMIA
- Bendamustine for the treatment of multiple myeloma in first-line and relapsed–refractory settings: a review of clinical trial data
- (2014) Antonio Palumbo et al. LEUKEMIA & LYMPHOMA
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BCL2 for the Treatment of Lymphoid Malignancies
- (2014) Mary Ann Anderson et al. SEMINARS IN HEMATOLOGY
- Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
- (2014) D S Siegel et al. Blood Cancer Journal
- Therapeutic Advancements in Multiple Myeloma
- (2014) Alessandro Gozzetti et al. Frontiers in Oncology
- Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
- (2013) H. Ludwig et al. BLOOD
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC
- (2013) Sridurga Mithraprabhu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pomalidomide in the treatment of relapsed multiple myeloma
- (2013) Peter A Forsberg et al. Future Oncology
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- Bruton's tyrosine kinase: potential target in human multiple myeloma
- (2013) Ying Liu et al. LEUKEMIA & LYMPHOMA
- New orally active proteasome inhibitors in multiple myeloma
- (2013) Alessandro Allegra et al. LEUKEMIA RESEARCH
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
- (2013) V Munugalavadla et al. ONCOGENE
- Decoding the Pathophysiology and the Genetics of Multiple Myeloma to Identify New Therapeutic Targets
- (2013) Panisinee Lawasut et al. SEMINARS IN ONCOLOGY
- A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo
- (2013) J Glauer et al. Blood Cancer Journal
- Multiple myeloma
- (2013) D. Smith et al. BMJ-British Medical Journal
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
- (2012) S. Lentzsch et al. BLOOD
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB
- (2012) Stuart A. Rushworth et al. CELLULAR SIGNALLING
- Molecular pathogenesis of multiple myeloma and its premalignant precursor
- (2012) W. Michael Kuehl et al. JOURNAL OF CLINICAL INVESTIGATION
- Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance
- (2012) David S. Siegel SEMINARS IN HEMATOLOGY
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
- (2011) M. Cavo et al. BLOOD
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
- (2009) C B Reeder et al. LEUKEMIA
- Dysfunctional homologous recombination mediates genomic instability and progression in myeloma
- (2008) M. A. Shammas et al. BLOOD
- Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
- (2008) Gema Mateo et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system
- (2008) C L H Snozek et al. LEUKEMIA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now